
Post-Infectious Irritable Bowel Syndrome



John K. Marshall MD
Division of Gastroenterology
McMaster University



Pathogenesis of IBS





Enck P. Nat Rev Dis Primers 2016;2:16014

Post-Infectious Irritable Bowel Syndrome


Stewart GT.
 Post-dysenteric colitis.
 BMJ 1950;1:405-9

- Chaudhary NA, Truelove SC.
 The irritable colon syndrome.
 Q J Med 1962;31:3-7-22
- Hunt RH, O'Brien M, Milton-Thompson GJ Stress and the enteron.
 J Royal Nav Med Service 1974;69:49-51



Post-Infectious Irritable Bowel Syndrome

 Altered bowel habit and abdominal discomfort that persist after acute enteric infection despite clearance of the inciting pathogen and recovery from the acute illness



Walkerton, Ontario





- Agricultural community
- Population ~5000
- 180km NW of Toronto
- Groundwater supply: 3 drilled wells with chlorination units













Walkerton: May 2000

Outcome:	N
Reported cases of acute GE	1346
Affected Walkerton residents	799
Field epidemiology estimate of acute GE	2321
Affected Walkerton residents	1286
Hospitalizations*	65
Documented hemolytic uremic syndrome+	27
Attributable deaths	6

* 55% age 0 to 8 + 52% age 1 to 4



Walkerton Health Study

THE WALKERTON HEALTH STUDY 2002-2008



Final Report

Submitted to the

Ontario Ministry of Health and Long-Term Care

Prepared by

William F. Clark MD¹, Jennifer J. Macnab PhD², Jessica M. Sontrop PhD² on behalf of the WEL Investigators of the Walkerton Health Study

- Division of Nephrology, Department of Medicine, University of Western Ontario, London, Ontario, Canada.
- Department of Epidemiology & Biostatistics, University of Western Ontario, London, Ontario, Canada.












- Funded by Ontario MOH and CCFC
- Multidisciplinary team:
 - Nephrology, ID (UWO)
 - GI (McMaster)
- Mission: study long-term health outcomes and facilitate local access to medical care
- Longitudinal cohort study 2001-2008
- Recruitment through local town hall meetings and advertisements
- In-person annual standardized interviews and assessments
- Total enrolment: N=4561



Incidence of IBS 2 Years After Acute Gastroenteritis in Walkerton Ontario








IBS After Infectious Enteritis: Systematic Review and Meta-Analysis


Author, Year	n/N	Event Rate (95% OI)
Bacterial		
Bettes, 2014	101/425	0.238 (0.200-0.280)
Cremon, 2014	33/204	0.162 (0.117-0.219)
Nielson, 2014	56/268	0.209 (0.164-0.262)
Kah, 2012	6/65	0.092 (0.042-0.191)
Youn. 2012	17/124	0.137 (0.087-0.210)
Schwille Kiuntke, 201	1 22/48	0.458 (0.324 0.599)
Lim, 2010	11/71	0.155 (0.088-0.259)
Thabano, 2010	32/305	0.105 (0.075-0.145)
Jung, 2009	12/87	0.138 (0.080-0.227)
Saps, 2008	14/44	0.318 (0.198-0.468)
Piche, 2007	1/23	0.043 (0.006-0.252)
Ruigomez, 2007	167/5894	0.028 (0.024-0.033)
Spence, 2007	49/547	0.090 (0.068-0.117)
Borgaonkar, 2006	7/191	0.037 (0.01B-0.075)
Marshall, 2006	417/1368	0.305 (0.281-0.330)
Ji. 2005	15/101	0.149 (0.092-0.232)
Mearin, 2005	31/271	0.114 (0.082-0.158)
Okhuysen, 2004	7/61	0.115 (0.056-0.222)
Wang, 2004	24/295	0.081 (0.055-0.119)
Dunlop, 2003	103/747	0.138 (0.115-0.165)
Parry, 2003	18/108	0.167 (0.108-0.249)
Gwee, 1999	22/109	0.202 (0.137-0.288)
Neal, 1997	23/366	0.063 (0.042-0.093)
McKendrick, 1994	12/38	0.316 (0.189 0.478)
	1200/11760	0.138 (0.094-0.199)
Protozoal/Parasitic		P=98%
Hanevik, 2014	291/748	0.389 (0.355-0.424)
Wensaas, 2012	355/817	0.435 (0.401 0.469)
Hanevik, 2009	66/82	0.805 (0.705-0.877)
Soyfurk, 2007	5/72	0.069 (0.029-0.156)
	717/1719	0.419 (0.287-0.565)
Viral		I ² =9556
Porter, 2012	7/1718	0.004 (0.002-0.009)
Zanini, 2012	40/17B	0.225 (0.169-0.292)
Saps, 2009	4/44	0.091 (0.035 0.218)
Marshall, 2007	13/86	0.151 (0.090-0.243)
	64/2026	0.064 (0.011-0.296)
		F=97%



- 45 studies (N=21,421)
- Follow-up 3 months to 10 years
- Relative risk for IBS if infectious enteritis in last 12 months:
 - 4.2 (95% CI 3.1-5.7)
- Pooled PI-IBS prevalence
 - 10.1% (95% CI 7.2-14.1) at 12 months
 - 14.5% (95% CI 7.7-25.5) > 12 months
- Risk factors for PI-IBS:
 - Female: OR 2.2 (1.6-3.1)
 - Antbiotics: OR 1.7 (1.2-2.4)
 - Anxiety: OR 2.0 (1.3-2.9)
 - Depression: OR 1.5 (1.2-1.9)
 - Somatization: OR 4.1 (2.7-6.0)
 - Neuroticism: OR 3.3 (1.6-6.5)
 - Clinical indicators of enteritis severity





PI-IBS After Viral Gastroenteritis





A Risk Score for Post-Infectious Irritable Bowel Syndrome





Risk Score Ranges from 0 to 90:


Low (<42) = 10%, Intermediate (43-68) = 35%, High (>69) = 60%

Age under 60 = 6; female =9; duration more than 7 days =7; maximum stool frequency more than 6 =6; bloody stool = 4; abdominal cramps = 32; fever = 5; weight loss over 10 pounds = 8; premorbid anxiety/depression = 1; post infectious anxiety/depression = 10




Persistence of PI-IBS Symptoms

(among subjects with IBS in 2002/2003)





Stability of IBS Phenotype






Long-Term Clinical Course of Shigellosis: 10-Year Follow-Up Study

- Prospective cohort study of 2001 Shigella outbreak in Korea
- 124 hospital employees infected by Shigella sonnei due to contaminated cafeteria food
- 105 age- and gender-matched non-infected controls

S	Shigella-exposed group		Control group		Adjusted OR	
Survey time (yr) -	Total No.	No. of IBS	Total No.	No. of IBS	(95% CI)	
1st	87	12 (13.8%)	89	1 (1.1%)	11.9 (1.49-95.58)	
3rd	87	13 (14.9%)	89	4 (4.5%)	3.93 (1.20-12.86)	
5th	53	11 (20.8%)	49	6 (12.2%)	1.88 (0.64-5.54)	
8th	71	11 (15.4%)	65	6 (9.2%)	1.87 (0.62-5.19)	
10th	86	20 (23.3%)	76	15 (19.7%)	1.61 (0.70-3.69)	




Luminal and Mucosal Factors in the Pathogenesis of IBS





Increased Intestinal Permeability with IBS in Walkerton Ontario








Genetic Associations with PI-IBS

Gene ID	Gene Category	SNP ID	Associated Allele	Frequency Controls	Frequency Cases	Odds Ratio (95% CI)	p value
TLR9	Innate immunity	P545P rs352139	Α	41%	48%	1.38 (1.10-1.73)	0.0059
TLR9	Innate immunity	-T1237C rs5743836	Т	82%	87%	0.69 (0.50-0.95)	0.025
IL-6	Innate immunity	-G174C rs1800795	С	39%	44%	1.28 (1.01-1.64)	0.042
CDH1	Intestinal epithelial barrier	-C160A rs16260	Α	26%	31%	1.26 (0.99-1.61)	0.035

IL-6 and CDH1 associations stronger when analysis restricted to subjects with confirmed gastroenteritis exposure









Genetic Variants are Independent PI-IBS Risk Factors


Multiple Logistic Regression Controlling for Clinical Predictors

Variables	Reference	P value	Odds ratio (95% confidence interval)
rs5743836:T (<i>TLR9</i>)	С	.0168	1.536 (1.080-2.182)
rs2069861:T (IL6)	С	.0345	1.509 (1.031-2.209)
rs16260:A (CDH1)	С	.0143	1.398 (1.069-1.829)
Age (y)		.0159	0.986 (0.975-0.997)
Gender	Female	.0238	1.521 (1.057-2.187)
Features of acute enteric illness			
Duration of diarrhea			
2-3 d	0-1 d	.976	0.987 (0.428-2.275)
4-5 d	0-1 d	.363	1.484 (0.634-3.476)
6-7 d	0-1 d	.626	1.242 (0.519-2.977)
>7 d	0-1 d	.136	1.855 (0.823-4.183)
Bloody stools	No	.00338	1.845 (1.225-2.779)
Abdominal cramps	No	.000745	7.754 (2.258-25.499)
Weight loss (>10 lb)	No	.000921	2.064 (1.345-3.169)




Prevalence of Dyspepsia at 8 Years Using Rome II Definition

(Short-Form Leeds Dyspepsia Questionnaire)



Post-Infectious IBS After Long-Distance Travel

- Survey of 1190 long-distance travelers, 7 months after journey
 - Traveler's diarrhea (at least moderate) in 43.3%
 - New-onset IBS at 7 months post travel in 7.2% (95% CI 5.8-8.6)
 (10.7% if diarrhea during travel vs. 2.5% if no traveler's diarrhea)





Conclusions

- The Walkerton outbreak was an awful human tragedy
- The contributions of citizens of Walkerton have enhanced understanding of post-infectious IBS
- New insights:
 - Epidemiology and natural history
 - Adult
 - Adolescent
 - Risk factors and risk profiling
 - IBS phenotype stability
 - Risk of IBD
 - Role of intestinal permeability
 - Genetic risk factors



Acknowledgements

McGill University & Genome Quebec Innovation Centre

Alexandra-Chloe Villani, Genevieve Geneau, Alexandre Belisle Denis Franchimont

McMaster University

Stephen M. Collins, Marroon Thabane

University of Western Ontario

Bill Clark, Amit Garg, Jennifer MacNab

Ontario Institute for Cancer Research

Mathieu Lemire

Mayo Clinic

Yuri Saito

Study Participants



Crohn's and Colitis
Foundation of Canada

Fondation canadienne des maladies inflammatoires de l'intestin



The Ministry of Health and Long-Term Care













